Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda

@article{dYvoire2007PhysiologicallybasedKM,
  title={Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda},
  author={Michel Bouvier d’Yvoire and Pilar Prieto and Bas J. Blaauboer and Fr{\'e}d{\'e}ric Y. Bois and Alan R. Boobis and C{\'e}line Brochot and Sandra Coecke and Andreas P. Freidig and Ursula Gundert-Remy and Thomas Hartung and Miriam Naomi Jacobs and Thierry Lavé and David E. Leahy and Hans Lennern{\"a}s and George D Loizou and Bette Meek and Camilla Pease and Malcolm Rowland and M. Spendiff and Jiansong Yang and Marco J. Zeilmaker},
  journal={Alternatives to Laboratory Animals},
  year={2007},
  volume={35},
  pages={661 - 671}
}
Physiologically-based Kinetic Modelling (PBK Modelling) : Meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63 

Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework.

The aim of this conceptual framework paper is to contribute to the further development of the modelling of effects of drugs or toxic agents by an approach which is based on the underlying physiology and pathology of the biological processes by employing approaches to bridge the gap between systems biology and physiologically based kinetic and dynamic models.

LINKING MULTIMEDIA ENVIRONMENTAL AND PBPK MODELS TO ASSESS HEALTH RISKS – A CASE STUDY

This research presents a probabilistic approach to estimating human exposure to chemicals through multiple pathways by calculating the distribution of contaminants among products using so-called ‘multimedia models’.

Physiologically based modelling and prediction of drug interactions.

  • F. Bois
  • Biology, Chemistry
    Basic & clinical pharmacology & toxicology
  • 2010
Past developments in the area of physiologically based pharmacokinetic (PBPK) modelling of interactions are reviewed and a systems biology approach to the question is demonstrated, and the capabilities of new software tools to facilitate that development are demonstrated.

Computational Toxicology Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making

The challenges in applying PBK modelling to support regulatory decision making under the toxicology and risk-assessment paradigm shift towards animal replacement are discussed and the potential applications of next generation (NG)-PBK modelling, based on new data streams are highlighted.

EURL ECVAM WORKSHOP ON NEW GENERATION OF PHYSIOLOGICALLY-BASED KINETIC MODELS IN RISK ASSESSMENT

In the workshop, using presentations and discussions, experts elaborated on the importance of being transparent about the model construct, assumptions, and applications to support assessment of model credibility and offered several recommendations to address commonly perceived limitations of parameterization and evaluation of PBK models developed using non-animal data.

Tutorial on physiologically based kinetic modeling in molecular nutrition and food research.

Physiologically based kinetic (PBK) modeling provides an important tool in the field of the 3Rs aiming at Replacement, Reduction and Refinement of animal studies and may also be a useful tool for risk assessment.

A Workflow for Global Sensitivity Analysis of PBPK Models

The elements of a workflow for SA of PBPK models that is computationally feasible, accounts for interactions between parameters, and can be displayed in the form of a bar chart and cumulative sum line (Lowry plot) are defined, which are believed to be intuitive and appropriate for toxicologists, risk assessors, and regulators.
...

References

SHOWING 1-10 OF 35 REFERENCES

Extrapolation of physiological parameters for physiologically based simulation models.

Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment

A six‐step process for model evaluation that relies on multidisciplinary expertise to address the biological, toxicological, mathematical, statistical, and risk assessment aspects of the modeling and its application is described.

The Necessity of Biokinetic Information in the Interpretation of In Vitro Toxicity Data

  • B. Blaauboer
  • Biology, Chemistry
    Alternatives to laboratory animals : ATLA
  • 2002
Possibility of biokinetic modelling on the basis of in vitro and other non-animal data are discussed, and the application of the results in hazard and risk-assessment schedules is considered.

Whole Body Pharmacokinetic Models

It is concluded that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes.

Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

  • H. BartonW. Chiu Y. Tan
  • Environmental Science
    Toxicological sciences : an official journal of the Society of Toxicology
  • 2007
The multidisciplinary dialogue initiated by this Workshop will foster the collaboration, research, data collection, and training necessary to make characterizing uncertainty and variability a standard practice in PBPK modeling and risk assessment.

Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures.

The ability to predict the kinetics of chemicals in complex mixtures by accounting for binary interactions alone within a PBPK model is a significant step toward the development of interaction-based risk assessment for chemical mixtures.

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

An effort to build virtual populations using extensive demographic, physiological, genomic and in vitro biochemical data to simulate and predict drug disposition from routinely collected in vitro data is outlined.

APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA

It is concluded that the generic PBPK model is potentially a powerful and cost-effective tool for predicting the mammalian pharmacokinetics of a wide range of organic compounds, from readily available in vitro inputs only.

A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures.

The approaches developed in the present study permit, for the first time, the consideration of the impact of multichemical pharmacokinetic interactions at a quantitative level in mixture risk assessments.